Skip to main content

Factors affecting pathways to care for children and adolescents with complex vascular malformations: parental perspectives

Abstract

Background

Complex vascular malformations (VMs) are rare disorders that can cause pain, coagulopathy, disfigurement, asymmetric growth, and disability. Patients with complex VMs experience misdiagnosis, delayed diagnosis, delayed or inappropriate treatments, and worsened health. Given the potential consequences of delaying expert care, we must identify the factors that impede or facilitate this access to care.

Results

We performed semi-structured interviews with 24 parents (21 mothers; 3 fathers; median age = 42.5 years) of children with complex VMs and overgrowth disorders living in the US, recruited through two patient advocacy groups – CLOVES Syndrome Community, and Klippel-Trenaunay Support Group. We performed thematic analysis to assess parental perspectives on barriers and facilitators to accessing expert care. We identified 11 factors, representing 6 overarching themes, affecting families’ ability to access and maintain effective care for their child: individual characteristics (clinician behaviors and characteristics, parent behaviors and characteristics), health care system (availability of specialist multidisciplinary teams, care coordination and logistics, insurance and financial issues, treatments and services), clinical characteristics (accuracy and timing of diagnosis, features of clinical presentation), social support networks, scientific progress, and luck and privilege. Additionally, access to information about VMs and VM care was a crosscutting theme affecting each of these factors. These factors influenced both the initial access to care and the ongoing maintenance of care for children with VMs.

Conclusion

Parents of children with VMs report multiple factors that facilitate or impede their ability to provide their child with optimal care. These factors represent possible targets for future interventions to improve care delivery for families affected by VMs.

Introduction

Vascular malformations (VMs) are rare disorders that affect the development, structure, and/or function of vasculature in children [1, 2]. Some complex VMs are associated with syndromes caused by genetic variants that lead to overgrowth, such as Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevis, Skeletal anomalies (CLOVES) and Klippel-Trenaunay syndromes [1, 3]. These complex VMs can cause pain, coagulopathy, disfigurement, asymmetric growth, and disability [3]. Furthermore, these disorders can lead to social stigmatization and myriad uncertainties for families [4,5,6,7].

In recent years, discoveries of genetic drivers for VMs have led to new disease classifications and novel treatment options. For example, somatic PIK3CA variants drive the growth of many VMs, as well as somatic overgrowth syndromes [8]. With these discoveries, many patients with VMs might now benefit from treatment with targeted inhibitors [9,10,11]. in addition to surgery and/or interventional radiology procedures.

Given this rapid evolution of knowledge and availability of novel treatments, it is imperative that patients with complex VMs receive expert medical care coordinated between primary and specialist teams. Pediatricians play a pivotal role in identifying vascular lesions, facilitating initial workup, providing referrals, and collaborating with specialists to maintain the child’s health. Due to the rarity of these conditions and complex presentation of symptoms, many pediatricians are unfamiliar with VMs, which can lead to misdiagnosis, delayed diagnosis, delayed or inappropriate treatments, and worsened health [12, 13]. Given the potential consequences of delaying coordinated care with VM specialists, it is essential to identify factors that impede or facilitate the ability of families to access and maintain this complex care. However, almost no studies have evaluated care delivery for patients with VMs, despite a growing body of research in other rare diseases [14,15,16]. In this qualitative study, we aimed to identify these barriers and facilitators from the perspectives of parents whose children have complex VMs.

Results

Participant characteristics

We performed 24 interviews, ranging from 39 to 73 min. Participating caregivers were predominantly White (n = 22, 92%), female (n = 21, 87), and had college or professional degrees (n = 8, 33% and n = 7, 29%, respectively). Parents’ ages ranged from 21 to 54 years (mean 41 years). (Table 1) Participants cared for children ranging in age from infancy to 16 years (median 11 years). (Table2) Approximately equal proportions of male and female children were represented, and all children’s care was covered by health insurance. Parents reported a high disease severity (median 8/10, Interquartile Range: 5–9) and interference of disease in the child’s life (median 7.5/10, Interquartile Range 6–9). Participants resided in 14 different states, representing multiple regions of the US.

Table 1 Participant demographics
Table 2 Child characteristics

Factors affecting access and maintenance of health care

We identified 11 factors, representing 6 overarching themes, affecting families’ ability to access and maintain effective care for their child. (Additional file 1: Fig. S1) Additionally, access to information about VMs and VM care was a crosscutting theme affecting each of these factors. See below and Table 3 for illustrative excerpts.

Table 3 Representative excerpts from transcripts

Individual characteristics

All parents (n = 24/24) described individual characteristics and behaviors of clinicians and parents. Clinician characteristics included knowledge, investment of effort, and helpfulness. Clinician behaviors such as facilitating referrals, escalating care, and providing validation/support were also important. Parents described how most non-specialist physicians lacked knowledge about their child’s disease. Parents found it helpful when physicians admitted their limitations and referred them to other specialists. Yet, some physicians were not willing to offer referrals or second opinions. Parents appreciated clinicians who advocated for their child and demonstrated commitment and investment. Some parents, however, did not find physicians who seemed dedicated to taking extra steps to help their family: “That’s one thing that I wish I had more, someone to lead the way. I felt lost. I felt alone. I didn’t know what to do. I felt completely helpless.” [CAR 20].

When clinicians were uninformed or dismissive, parents were burdened with doing their own research to educate clinicians and coordinate care. Consequently, parents’ own individual characteristics and behaviors supported their child’s care. Parents described a ceaseless drive to advocate for their child: “Out of desperation, I just felt relentless that I had to keep advocating and finding different avenues whenever we did find providers who wouldn’t help us or who didn’t know what to do.” [CAR 1] Several parents described the need to advocate because many clinicians lacked sufficient knowledge about these rare disorders. Advocacy included educating oneself about the diagnosis and speaking out on behalf of their child. This parental drive to advocate increased when clinicians lacked sufficient concern, treatments failed to improve symptoms, and physicians seemed to lack knowledge or competence.

Health care system

All parents (n = 24/24) described health care system factors, including access to multidisciplinary teams, care coordination, navigating insurance, and finding treatments and services locally. Given the rarity and complexity of these diseases, parents described the importance of multidisciplinary teams with expertise in VMs. Accessing these teams facilitated accurate diagnosis and treatment after parents struggled to find answers for months or years. These teams were critical because many physicians lacked knowledge of VMs, especially local, non-specialist physicians. However, most parents described difficulties accessing multidisciplinary teams. Many families had to travel long distances: “It’s hard. It’s 1000 miles one way.”[CAR 39] One parent was grateful they “only” had to drive 6 h to see their clinical team. For some, this distance prevented them from establishing continuous care. Also, parents often had to wait several months for an appointment with these specialist clinics.

Given the complexity of care and scarcity of experts, many parents described the burden of coordinating care. One parent called it a “full-time job.” [CAR 19] Another parent resigned from her professional job to coordinate her child’s care. To access multidisciplinary teams, parents needed to complete multiple forms and collect medical information from multiple sources. This process was intimidating for parents who lacked experience with the medical system. Parents also found it exhausting to coordinate information among physicians when their child’s care included multiple clinicians in different locations.

Seeking care from multiple doctors across different health care systems and states created challenges with insurance coverage and financial strains. Parents must pay multiple co-pays for visits at multidisciplinary clinics. Some parents were forced to transfer care to local clinicians with limited expertise in VMs, or pay out-of-pocket for care, due to insurance denials. Other parents had to contact the clinical team and insurance company repeatedly to ensure they received prior authorization for care. Furthermore, insurance often failed to cover essential equipment, such as compression garments or specialty shoes. Even with high-quality insurance coverage, many families still felt financial strain: “We're really fortunate to have insurance, and it's still been a financial burden. I can't imagine what it would be like if we didn't.” [CAR 29].

Parents often needed to seek treatments and services locally, at the direction of their specialist team. However, several parents described the challenges of accessing these services locally, especially in rural settings. Because of these limitations, some parents opted to travel long distances rather than rely on local services.

Clinical characteristics

Most parents (n = 23/24) described clinical characteristics, including achieving an accurate diagnosis and unique features of their child’s clinical presentation.

For many parents, an early and accurate diagnosis facilitated finding information about their child’s condition and identifying expert physicians. However, many families went months or years with inaccurate or incomplete diagnoses, leading to feelings of frustration and worry: “It's hard to describe how helpless you feel when you don’t know what it is. Because you don’t have a path forward.” [CAR 19].

Parents also described clinical features of their child’s condition that affected their pathway to care. Manifestations visible on the skin or observed on prenatal screening ultrasound often led to early evaluation, although early investigation did not necessarily lead to earlier diagnosis. In fact, it often resulted in numerous unnecessary tests and procedures. Additionally, severe and rapidly progressing symptoms led to early evaluation by clinicians.

Social support networks

Many parents (n = 18/24) described the role of social support networks, including social media and patient advocacy websites. Members of these social networks provided families with advice about clinicians, treatments, and symptoms. These groups provided reassurance to families as they navigated uncertainties. Some parents also received financial support from advocacy groups. Yet, parents also recognized the downsides of social networks, such as incorrect guidance and emotional distress from learning about other children with severe disease manifestations.

Scientific progress

Many parents (n = 12/24) described the state of scientific progress. Parents often reported the lack of existing information about their child’s condition, which limited their treatment options and their ability to understand how their child’s condition would progress. Some parents lamented a lack of interest from scientists and companies in researching these rare diseases. When research studies and clinical trials were available, some parents described how these studies provided pathways to achieving a diagnosis or receiving treatment. The paucity of research opportunities led some parents to feel obligated to participate in studies, which they perceived as both beneficial and burdensome.

Luck and privilege

Several parents (n = 8/24) described personal privilege and luck. Parents acknowledged how financial security permitted them to travel to distant medical centers and take time off work. Other parents benefitted from prior medical training. Even with these opportunities and privileges, several parents still attributed their ability to access care to luck. For example, one parent described encountering a physician who happened to read an article on the child’s disease the week before their appointment: “When you think about this journey, him having read that paper, if he hadn't, I don't know where we would be right now.” [CAR 36] Other parents described how their physicians had experience caring for one previous patient with this disease, or how they serendipitously met a clinician with interest and experience in VMs. Furthermore, some parents expressed gratitude that they happened to live near a multidisciplinary team.

The central role of information

Information played a central role in facilitating access and maintenance of expert care, influencing factors across all levels. Parents needed accurate information about the diagnosis, symptoms, progression, treatments, research opportunities, and experts in VMs to identify appropriate next steps. Yet, parents often received incomplete, inaccurate, or conflicting information from their clinicians. As a result, many parents relied on the internet and social media as information sources. Even when parents did locate information about VMs, they reported it was often difficult to find information relevant to their child’s unique medical needs.

Obtaining information was often the goal of parental advocacy, and information deficiencies reinforced the need for ongoing advocacy. Parents’ ability to find high-quality information was also affected by paywalls on scientific articles. Furthermore, the lack of scientific progress contributed to limited information: “I'll never forget, whenever I got that diagnosis, they gave me a printout that was two pages front and back. There was really, even on the internet, very, very limited information.” [CAR 37] Information about available studies and clinical trials (often from social media) also helped advance this science by recruiting families for studies. Without information, parents felt lost: “Just imagine being in a super dark hole and having no clue where to go.” [CAR 43].

Discussion

Parents of children with complex VMs identified barriers and facilitators to care that manifested across 6 levels ranging from individual behaviors to systemic policies and structures. (Fig. 1) Parental advocacy seems to play a disproportionately large role in families’ pathways to care, suggesting that parents of children with complex VMs might be at increased risk of caregiver burden and children with complex VMs might struggle to receive adequate care. Increased parental advocacy was a response to multilevel barriers, including lack of knowledge among clinicians, distance to multidisciplinary clinics, scarcity of local treatments and services, complex care coordination demands, and financial strains related to insurance coverage and travel costs. Health insurance coverage, in particular, created many challenges for families. For example, insurance policies dictated whether families could be seen by clinicians with VM expertise and how much this care would cost out-of-pocket. Furthermore, families spent great effort to ensure they received prior authorization for care to avoid unexpected and costly bills.

Fig. 1
figure 1

Factor affecting pathways to care

These burdens were enduring, meaning that even if families were able to initially access expert care, these barriers often prevented them from maintaining continuity of care. Consequently, families with lower household income, more restrictive insurance, or who live far from specialist teams are likely at a higher risk of delayed diagnosis and insufficient care. For example, in other rare diseases, distance from a tertiary center was associated with misdiagnosis and delayed diagnosis [17, 18] Future work should identify which families are at the highest risk of disparate medical care to support equitable health care delivery. Improving this care might require proactive outreach from VM specialists to community physicians. Additionally, specialists might leverage remote visits and telehealth to better coordinate generalist and specialist care for these families.

Parents identified information needs as a significant thread influencing many of these factors. Insufficient information is a common barrier in the context of rare diseases [19]. These limitations in quantity and quality of information can lead parents to scavenge multiple information sources, including peer support, internet searches, and social media [20, 21]. Information barriers in rare diseases have also been linked to delays in diagnosis and misdiagnosis [18, 22] Similarly, studies have demonstrated deficiencies in clinician knowledge about rare diseases and called for trustworthy, accessible information sources for clinicians [23] Parents of children with rare disorders frequently report knowing more about the disease than their clinicians, which can lead to complications in the clinical relationship and diminished trust [24, 25] Our findings suggest that, in the context of complex VMs, parents' increased advocacy and information-seeking results in them knowing more about the disease and system of care. Consequently, the burden of education and care coordination of care falls on parents. Future work should develop accessible and reliable sources of information for families affected by complex VMs and clinicians. For example, researchers and funding agencies might prioritize open access publications with accompanying lay summaries. Additionally, clinicians and researchers might develop and disseminate reliable medical information to families in print and video, while ensuring to incorporate families in this development process. Academic institutions could incentivize this work by considering these materials to be academic contributions that support career advancement and promotions.

Several factors were instrumental in helping families access expert care. Clinician advocacy and support played a significant role. Patients with rare diseases often encounter clinicians who are dismissive and unwilling to investigate symptoms or treatments further [26]. In the context of complex VMs, parents were grateful for clinicians who validated their concerns, researched symptoms and treatment options, facilitated referrals to specialists, and showed a genuine willingness to help. Social media also played a central role in helping parents find expert clinicians, achieve a diagnosis, learn about new treatments and research opportunities, and prepare for future symptoms and health needs. Patients with rare diseases are more likely than other health information consumers to rely on social networks for information [27]. Often, patients and parents turn to social media when they feel dismissed by clinicians. Social media also helps parents and families connect with similarly affected families and identify new research opportunities [28,29,30]. Finally, in the context of complex VMs, luck and privilege often plays a role in locating and maintaining expert care. Again, this finding suggests that future work should evaluate for potential health disparities in the care of complex VMs related to privilege based on location, income, education, and health literacy.

Our results should be interpreted in light of limitations. We recruited participants from patient advocacy groups with social media footprints. This approach allowed us to recruit geographically diverse participants and participants who have not been able to access expert care. However, our sample was predominantly White, female, and well educated with high incomes. Also, these families had already accessed patient support groups and have already arrived at a diagnosis. As such, our results might underrepresent the barriers that impede diagnosis, as well as access and maintenance of expert care. Future studies should aim to recruit purposively from advocacy groups and specialty clinics to ensure geographic, racial, and socioeconomic diversity. Parents of children with more severe disease might also be more likely to participate in patient advocacy groups. Furthermore, parents might have been affected by recall bias or conformity bias. Due to our recruitment strategy, we do not have access to additional clinical information that could inform the interpretation of these results. Lastly, we did not evaluate the perspectives of patients themselves, who might experience unique challenges and barriers as they transition to self-management in young adulthood.

Conclusion

Parental interviews provided evidence for 6 themes of factors that facilitate or impede access to expert care for complex VMs. These factors manifest across multiple levels, ranging from individual behaviors to systemic structures and policies. Due to limited support, parents must strongly advocate for effective, coordinated care for their child when experiencing multilevel barriers to care. Future studies should aim to intervene upon these multilevel barriers to ensure equitable access to care for all patients with complex VMs.

Methods

We report this study following Consolidated Criteria for Reporting Qualitative Research guidelines [31] (Appendix 1).

Participants and recruitment

We interviewed parents of children with VMs, recruiting from two patient support groups: Klippel-Trenaunay (K-T) Support Group and CLOVES syndrome community. Caregivers were eligible if they were (1) 18 years or older, (2) spoke English, (3) lived in the US, (4) had a child younger than 18 years with a VM. No participants had clinical relationships with investigators. To engage these communities, we led an informational webinar and posted recruitment flyers via these organizations’ websites and social media platforms. We purposively sampled for fathers and racial minorities, but recruitment was affected by the limited diversity of the organizations’ memberships. To ensure thematic saturation, we aimed to recruit at least 20 participants [32]. We obtained verbal informed consent, and the institutional review board at Washington University approved this study.

Data collection

Interviews occurred between June and October 2021. Participants completed a brief demographic survey in which race and ethnicity were self-reported. This survey included two questions that addressed the severity of illness and interference with their child’s life, with higher scores indicating greater severity and greater interference: (1) “On a scale of 1–10, to what extent do you think that your child's health problem is severe?”; (2) On a scale of 1–10, to what extent do you think that your child's health problem interferes in their life?” We conducted semi-structured interviews via telephone or video-conferencing software. We developed and refined the interview guide based on our prior wor [4,5,6,7, 33] and continued engagement with 3 parent advocates whose children had VMs. (Appendix 2) This guide explored characteristics of the child’s disease, barriers and facilitators to accessing medical care, and communication experiences. Two authors conducted interviews: BAS is a pediatric oncology physician specializing in VMs; AK is a medical educator with a PhD in communication. Only one interviewer was present during each interview. Both authors had led multiple prior qualitative studies. Interviews were audio-recorded and professionally transcribed.

Data analysis

We performed descriptive statistical analysis of the demographic survey using Microsoft Excel 2016, calculating proportion, median, and interquartile range.

We employed thematic analysi [34]. to identify factors that influenced parental access to and maintenance of expert care. We adopted the Agency for Healthcare Research and Quality’s four components of access to care: coverage, services, timeliness, and workforce [35]. BAS and AK read all transcripts to familiarize themselves, then descriptively coded 5 transcripts to formulate preliminary categories and themes. The authors assigned each code to a category, then collapsed these categories into representative themes. These categories and themes were then refined through iterative cycles of independent coding and consensus meetings. After reviewing 10 transcripts, we reached saturation for representative themes. Using this finalized codebook (Table 4), BAS and AK then coded all 24 transcripts by independently coding transcripts, reviewing the other’s application of codes, marking disagreements, and resolving disagreements through discussion. A third coder (KAK) reviewed 25% of transcripts to assess for agreement with thematic coding and resolved any disagreements with BAS to confirm coding validity. We coded transcripts using Dedoose qualitative software. The results presented represent 100% coder agreement.

Table 4 Codebook definitions

Availability of data and materials

The raw data generated and/or analyzed during the current study are not publicly available due ethical restrictions related to ensuring confidentiality, but de-identified data are available from the corresponding author on reasonable request.

Abbreviations

VM:

Vascular malformation

CLOVES:

Congenital lipomatous overgrowth, vascular malformations, epidermal nevis, skeletal anomalies

References

  1. Wolfe AD. Pediatric vascular anomalies: opportunities in primary care. In: Kamat DM, Frei-Jones M, editors. Benign hematologic disorders in children: a clinical guide. Cham: Springer International Publishing; 2021. p. 453–86.

    Chapter  Google Scholar 

  2. Anomalies ISftSoV. ISSVA Classification of Vascular Anomalies 2018 [updated 2018. Available from: https://www.issva.org/classification.

  3. Trenor CC, Adams DM, editors. Vascular anomalies: a guide for the hematologist/oncologist. 1st ed. Switzerland: Springer International Publishing; 2020.

    Google Scholar 

  4. Kerr AM, Haas SM. Parental uncertainty in illness: managing uncertainty surrounding an “orphan” illness. J Pediatr Nurs. 2014;29(5):393–400.

    Article  Google Scholar 

  5. Kerr AM, Harrington NG, Scott AM. Communication and the appraisal of uncertainty: exploring parents’ communication with credible authorities in the context of chronic childhood illness. Health Commun. 2017;34(2):201–11.

    Article  Google Scholar 

  6. Kerr AM, Harrington NG, Scott AM. Uncertainty management and decision making: parents’ experiences during their first visit to a multidisciplinary clinic for their child’s vascular anomaly. J Pediatr Nurs. 2020;52:18–24.

    Article  Google Scholar 

  7. Kerr AM, Thompson CM, Rubinsky V. Memorable messages parents of children with vascular birthmarks receive from others: implications for stigma and identity. Health Commun. 2020;35(6):685–95.

    Article  Google Scholar 

  8. Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations. Orphanet J Rare Dis. 2021;16(1):306.

    Article  Google Scholar 

  9. Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2): e20153257.

    Article  Google Scholar 

  10. Ricci KW, Hammill AM, Mobberley-Schuman P, Nelson SC, Blatt J, Bender JLG, et al. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. Pediatr Blood Cancer. 2019;66(5): e27614.

    Article  Google Scholar 

  11. Maruani A, Tavernier E, Boccara O, Mazereeuw-Hautier J, Leducq S, Bessis D, et al. Sirolimus (Rapamycin) for slow-flow malformations in children: the observational-phase randomized clinical PERFORMUS trial. JAMA Dermatol. 2021;157:1289.

    Article  Google Scholar 

  12. Donnelly LF, Adams DM, Bisset GS. Vascular malformations and hemangiomas. Am J Roentgenol. 2000;174(3):597–608.

    CAS  Article  Google Scholar 

  13. Mattila KA, Kervinen K, Kalajoki-Helmiö T, Lappalainen K, Vuola P, Lohi J, et al. An interdisciplinary specialist team leads to improved diagnostics and treatment for paediatric patients with vascular anomalies. Acta Paediatr. 2015;104(11):1109–16.

    Article  Google Scholar 

  14. Boettcher J, Boettcher M, Wiegand-Grefe S, Zapf H. Being the pillar for children with rare diseases-a systematic review on parental quality of life. Int J Environ Res Pub Health. 2021;18(9):4993.

    Article  Google Scholar 

  15. von der Lippe C, Diesen PS, Feragen KB. Living with a rare disorder: a systematic review of the qualitative literature. Mol Genet Genomic Med. 2017;5(6):758–73.

    Article  Google Scholar 

  16. Pelentsov LJ, Laws TA, Esterman AJ. The supportive care needs of parents caring for a child with a rare disease: a scoping review. Disabil Health J. 2015;8(4):475–91.

    Article  Google Scholar 

  17. Walter AL, Baty F, Rassouli F, Bilz S, Brutsche MH. Diagnostic precision and identification of rare diseases is dependent on distance of residence relative to tertiary medical facilities. Orphanet J Rare Dis. 2021;16(1):131.

    Article  Google Scholar 

  18. Dong D, Chung RY, Chan RHW, Gong S, Xu RH. Why is misdiagnosis more likely among some people with rare diseases than others? insights from a population-based cross-sectional study in China. Orphanet J Rare Dis. 2020;15(1):307.

    Article  Google Scholar 

  19. McMullan J, Crowe AL, Bailie C, Moore K, McMullan LS, Shamandi N, et al. Improvements needed to support people living and working with a rare disease in Northern Ireland: current rare disease support perceived as inadequate. Orphanet J Rare Dis. 2020;15(1):315.

    Article  Google Scholar 

  20. Litzkendorf S, Frank M, Babac A, Rosenfeldt D, Schauer F, Hartz T, et al. Use and importance of different information sources among patients with rare diseases and their relatives over time: a qualitative study. BMC Pub Health. 2020;20(1):860.

    Article  Google Scholar 

  21. Stanarević KS. Health information behaviour of rare disease patients: seeking, finding and sharing health information. Health Info Libr J. 2019;36(4):341–56.

    Article  Google Scholar 

  22. Llubes-Arrià L, Sanromà-Ortíz M, Torné-Ruiz A, Carillo-Álvarez E, García-Expósito J, Roca J. Emotional experience of the diagnostic process of a rare disease and the perception of support systems: a scoping review. J Clin Nurs. 2022;31(1–2):20–31.

    Article  Google Scholar 

  23. Ramalle-Gómara E, Domínguez-Garrido E, Gómez-Eguílaz M, Marzo-Sola ME, Ramón-Trapero JL, Gil-de-Gómez J. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis. 2020;15(1):18.

    Article  Google Scholar 

  24. Currie G, Szabo J. “It is like a jungle gym, and everything is under construction”: the parent’s perspective of caring for a child with a rare disease. Child Care Health Dev. 2019;45(1):96–103.

    Article  Google Scholar 

  25. Gomez-Zuniga B, Pulido Moyano R, Pousada Fernandez M, Garcia Oliva A, Armayones RM. The experience of parents of children with rare diseases when communicating with healthcare professionals: towards an integrative theory of trust. Orphanet J Rare Dis. 2019;14(1):159.

    Article  Google Scholar 

  26. Lian OS, Robson C. “It s incredible how much I ve had to fight” Negotiating medical uncertainty in clinical encounters. Int J Qual Stud Health Well-Being. 2017;12(sup2):1392219.

    Article  Google Scholar 

  27. Fox S. Peer-to-peer healthcare. (2011). Available from (https://www.pewresearch.org/internet/2011/05/12/peer-to-peer-healthcare-2/ [Last accessed 1/12/2022]

  28. Barton KS, Wingerson A, Barzilay JR, Tabor HK. “Before Facebook and before social media…we did not know anybody else that had this”: parent perspectives on internet and social media use during the pediatric clinical genetic testing process. J Commun Genet. 2019;10(3):375–83.

    Article  Google Scholar 

  29. Iyer AA, Barzilay JR, Tabor HK. Patient and family social media use surrounding a novel treatment for a rare genetic disease: a qualitative interview study. Genet Med Off J Am Coll Med Genet. 2020;22(11):1830–7.

    Google Scholar 

  30. Titgemeyer SC, Schaaf CP. Facebook support groups for pediatric rare diseases: cross-sectional study to investigate opportunities, limitations, and privacy concerns. JMIR Pediatr Parent. 2022;5(1): e31411.

    Article  Google Scholar 

  31. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.

    Article  Google Scholar 

  32. Guest G, Bunce A, Johnson L. How many interviews are enough? an experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.

    Article  Google Scholar 

  33. Sisk BA, Friedrich A, Blazin LJ, Baker JN, Mack JW, DuBois J. Communication in pediatric oncology: a qualitative study. Pediatrics. 2020;146(3): e20201193.

    Article  Google Scholar 

  34. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.

    Article  Google Scholar 

  35. Agency for healthcare research and quality: Elements of access to health care 2018 [1/5/2022]. Available from: https://www.ahrq.gov/research/findings/nhqrdr/chartbooks/access/elements.html.

Download references

Acknowledgements

We would like to thank the participants who contributed to this work in the hopes of improving care for others with vascular malformations in the future. We would like to thank all the parents and patients with vascular anomalies who participated and supported this project.

Funding

This study was funded by K-T Support Group and CLOVES Syndrome Community.

Author information

Authors and Affiliations

Authors

Contributions

BS participated in conceptualization, design, and implementation of the study, participated in formal analysis, drafted the initial manuscript, and reviewed and revised the manuscript. KK participated in formal analysis, and reviewed and revised the manuscript. AK participated in conceptualization, design, and implementation of the study, formal analysis, and reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Author information

BAS is a pediatric oncology physician specializing in VMs; AK is a medical educator with a PhD in communication. Both authors had led multiple prior qualitative studies. Interviews were audio-recorded and professionally transcribed. KK is a geneticist with expertise in caring for patients with VMs.

Corresponding author

Correspondence to Bryan A. Sisk.

Ethics declarations

Ethics approval and consent to participate

Ethical approval was given by Washington University School of Medicine Institutional Review Board (6202104047). Verbal consent was given by all participants after verbally reviewing study information.

Consent for publication

No personally identifiable data is contained in this article.

Competing interests

All authors declare that they do not have any competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig. S1

. Relationships between factors and themes

Appendices

Appendix 1 COREQ Checklist and Additional Information

Domain 1: Research team and reflexivity
Personal characteristics
Interviewer/facilitator Bryan Sisk (BAS) / Anna Kerr (AK) Title page
Credentials MD, MSCI / PhD Title page
Occupation Assistant Professor Pediatric Hematology and Oncology / Assistant Professor of Primary Care Title page
Gender Male/female
Experience and training BAS and AK are trained in qualitative research methods and have published qualitative research with patient/family participants Methods [6]
Relationship with participants
Relationship established BAS and AK held an informational webinar for interested participants Methods [5]
Participant knowledge of the interviewer BAS and AK introduced themselves and their roles in the project before each interview
Interviewer characteristics Participant were informed that BAS is a pediatric oncology physician specializing in vascular anomalies and AK is a medical educator with a PhD in communication Methods [5, 6]
Domain 2: Study design
Theoretical framework
Methodological orientation and theory Thematic analysis Methods [6]
Participant selection
Sampling Participants were recruited from two patient support groups Methods [5]
Method of approach Informational webinar and recruitment flyers via patient advocacy organizations’ websites and social media platforms Methods [5]
Sample size 24 Results [7]
Non-participation 25 participants were contacted. 1 participant did not answer during the scheduled interview
Setting
Setting of data collection Data were collected via videoconference and phone interviews Methods [5]
Presence of non-participants Non-participants may have been present if participants completed the interview in their home or another public setting
Description of sample 3 men, 21 women. Ages ranging from 21 to 54 years. 22 identified as White, 1 as Black or African American. 4 were Hispanic, Latin, or Spanish. Data collected between June and October 2021 Results [7] & Table 2
Data collection
Interview guide Interviews were semi-structured. The guide explored the child’s disease, barriers and facilitators to care, and communication experiences Methods [5]
Repeat interviews None
Audio/visual recording The interviews were audio-recorded Methods (6)
Field notes BAS and AK drafted memos after each interview of initial themes and insights
Duration Interviews ranged in duration from 39 to 73 min (M = 60 min) Methods [5]
Data saturation We reached saturation after coding 10 interviews Methods [5]
Transcripts returned No  
Domain 3: Analysis an findings
Data analysis
Number of data coders Three Methods [6]
Description of the coding tree Open coding, iterative thematic coding, and the coding validity check is described in methods Methods [6]
Derivation of themes We considered the Agency for Healthcare Research and Quality’s components of access to care while coding. However, final themes were derived during analysis Methods [6]
Software Dedoose Methods [6]
Participant checking None
Reporting
Quotations presented Participant quotations were used to illustrate the themes. All quotes were identified using the participant number Results [7,8,9,10,11,12] & Table 3
Data and findings consistent Data presented and the findings are consistent
Clarity of major themes Major themes are presented clearly in text, table, and figure formats Results [7,8,9,10,11,12], Fig. 1, & Table 3
Clarity of minor themes Minor themes are presented in-text and in a table Results [7,8,9,10,11,12] & Table 3

Appendix 2 VACOM-Caregiver: Interview guide (vascular anomalies communication)

figure afigure a

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sisk, B.A., Kerr, A. & King, K.A. Factors affecting pathways to care for children and adolescents with complex vascular malformations: parental perspectives. Orphanet J Rare Dis 17, 271 (2022). https://doi.org/10.1186/s13023-022-02432-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13023-022-02432-4

Keywords

  • Pediatrics
  • Vascular malformation
  • Vascular anomaly
  • Health care access
  • Communication
  • Rare disease